Medical Science News

RSS

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

New evidence implies that the Omicron variant may cause a less severe and/or faster recovery from clinical COVID-19 disease.

31 Dec 2021

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

Omicron infection induces cross-reactive immune responses

New research revealed that vaccine-breakthrough infections might elicit cross-reactive bNAbs against all variants of concern.

31 Dec 2021

COVID-19 vaccine appears safe in children aged 5–11 Years

A new report notes menial or nil severe adverse events from vaccination against COVID-19 in children and therefore recommends COVID-19 vaccination among children aged 5-11 years old.

31 Dec 2021

SARS-CoV-2 omicron variant may be less severe than the delta variant

A new study reveals that omicron infections in South Africa are associated with lower rates of hospital admissions and lower disease severity compared to beta and delta infections.

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

New study findings highlight the need for a rapid booster vaccine campaign to prevent COVID-19 caused by the Omicron variant since the neutralization of Omicron by the two-dose BNT162b2 vaccine is not effective in controlling the spread of the infection.

30 Dec 2021

Factors associated with SARS-CoV-2 breakthrough infection in fully vaccinated individuals

New study findings showed that the SARS-CoV-2 breakthrough infections are rare and show mild or asymptomatic profiles generally. The breakthrough infection occurs early after vaccination in almost 50% of the cases within 70 to 80 days post full vaccination.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

Study shows varying population immunity against SARS-CoV-2

Researchers analyzed the combined distribution of COVID-19 vaccination and prior SARS-CoV-2 infection in each state and county in the US since the beginning of the COVID-19 epidemic to estimate the changes in the population immunity during this period.

30 Dec 2021

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

A new study did not conclusively correlate the incidence of myocarditis or pericarditis with mRNA vaccination against SARS-CoV-2.

30 Dec 2021

Recombinant adjuvanted zoster vaccination associated with lower risk of COVID-19 diagnosis and hospitalization

A new study suggests that RZV may elicit durable innate immune responses in the elderly conferring heterologous protection against COVID-19. .

30 Dec 2021

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

A new study, focused on the SARS-CoV-2 Omicron variant, presented a modeling result from an analysis of genome surveillance data in Gauteng province, South Africa, using an existing estimation technique.

30 Dec 2021

SUSU researchers identify biological indicators of long-lasting PTSD

War veterans have helped scientists of South Ural State University identify biological indicators which signal whether people have a post-traumatic stress disorder or a susceptibility to it.

30 Dec 2021

SARS-CoV-2 infection can produce self-attacking autoantibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild symptoms or no symptoms at all, according to Cedars-Sinai investigators.

30 Dec 2021

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Researchers evaluated the humoral immunogenicity of a third COVID-19 mRNA vaccine dose in patients with inflammatory bowel disease.

30 Dec 2021

Promoting exercise as basic need for managing the physical and cognitive symptoms of MS

Citing recent evidence, experts in rehabilitation research advocate for integrating exercise into the care plans of persons with multiple sclerosis. The central role of the neurologist in clinical care offers an opportunity for this provider to promote exercise as fundamental for managing the physical and cognitive symptoms of MS.

30 Dec 2021

Medical Science News

Less severe clinical consequences of infection with SARS-CoV-2 Omicron variant

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Omicron infection induces cross-reactive immune responses

COVID-19 vaccine appears safe in children aged 5–11 Years

SARS-CoV-2 omicron variant may be less severe than the delta variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

Antibody neutralization of SARS-CoV-2 Omicron variant via BNT162b2 vaccine booster dose

Factors associated with SARS-CoV-2 breakthrough infection in fully vaccinated individuals

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

Study shows varying population immunity against SARS-CoV-2

Reviewing myocarditis and pericarditis in immunosuppressed individuals following COVID-19 mRNA vaccination

Recombinant adjuvanted zoster vaccination associated with lower risk of COVID-19 diagnosis and hospitalization

Study explores relative reproduction of the SARS-CoV-2 omicron variant in South Africa

SUSU researchers identify biological indicators of long-lasting PTSD

SARS-CoV-2 infection can produce self-attacking autoantibodies

Booster doses of mRNA vaccines improve humoral immunogenicity in patients with inflammatory bowel disease

Promoting exercise as basic need for managing the physical and cognitive symptoms of MS

Rapid antigen tests show lower sensitivity for Omicron than for earlier SARS-CoV-2 variants

Omicron analysis shows no clear evidence for increased virulence or lethality

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News